Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06426810 | Electrosurgical Bipolar Systems Versus Conventional Electrocautery After SLNBx | recruiting | N/A | 40 | SMG-SNU Boramae Medical CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06425874 | The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery | recruiting | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 22, 2024 |
| clinicaltrials |
| NCT06424054 | Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects(eChemoCoach) | not yet recruiting | N/A | 746 | Noordwest ZiekenhuisgroepOTHER | 0 | May 21, 2024 | clinicaltrials |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06214598 | Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors(AID) | recruiting | N/A | 90 | University of BelgradeOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06404697 | Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer(QUEEN-Dream) | not yet recruiting | Phase 2 | 73 | Fudan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04437602 | Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions(PROCEM) | active not recruiting | N/A | 441 | Region HallandOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05033756 | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO(COMPRENDO) | active not recruiting | Phase 2 | 11 | Institut fuer FrauengesundheitOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06401304 | Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)(OncoPROValue-1) | recruiting | — | 1,200 | Uppsala UniversityOTHER | 3 | May 6, 2024 | clinicaltrials |
| NCT05985551 | Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment(MagNeo) | active not recruiting | — | 114 | Uppsala UniversityOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03982485 | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer(APP) | active not recruiting | Phase 2 | 196 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06383663 | Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast Cancer | not yet recruiting | N/A | 452 | Sun Yat-sen UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05257577 | Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO)(FIBRATIO) | active not recruiting | — | 220 | Tampere University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | not yet recruiting | Phase 2 | 68 | Li HuipingOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast(COC-IDCB) | recruiting | Phase 1 | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04603209 | Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer | recruiting | — | 1,000 | Saint John's Cancer InstituteOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06149130 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | recruiting | Phase 2 | 82 | Tongji HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05800132 | Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI(IMA-L2) | recruiting | N/A | 5,000 | TherapixelINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02240836 | Energy Balance and Breast Cancer Aspects-II(EBBA-II) | active not recruiting | N/A | 545 | Oslo University HospitalOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT04672265 | Increasing Access to Breast Cancer Screening Among Immigrants | active not recruiting | N/A | 11,355 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06334471 | Whole Genome Sequencing in Breast Cancer(WGS SIT) | recruiting | — | 1,200 | Inocras Korea Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06340516 | NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity | recruiting | N/A | 700 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01996267 | Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2(TRAIN-2) | active not recruiting | Phase 3 | 437 | The Netherlands Cancer InstituteOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06330012 | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | recruiting | N/A | 50 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06330870 | Brain Metastasis Development Mechanism in BCBM Patients | recruiting | N/A | 30 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05433753 | Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study | recruiting | — | 60 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02474641 | Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer(HYPOSIB) | active not recruiting | N/A | 2,324 | University Hospital Schleswig-HolsteinOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321653 | Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes(AXILL-ART) | recruiting | — | 120 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | recruiting | Phase 2 | 120 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06319157 | Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction | recruiting | N/A | 94 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06315868 | Breast Cancer Subtype Characterization Through Patient's Derived Organoids.(BCinsightPDO) | recruiting | — | 306 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06313463 | Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy | recruiting | Phase 3 | 375 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer(APTneo) | active not recruiting | Phase 3 | 650 | Fondazione MichelangeloOTHER | 4 | Mar 6, 2024 | clinicaltrials |
| NCT05370300 | SNAPS Breast Cancer Patient Study Breast Cancer Patients | not yet recruiting | — | 500 | Immunis.AIINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05789901 | The MARVIN Chatbots to Provide Information for Different Health Conditions | recruiting | N/A | 400 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Mar 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 23, 2024source: clinicaltrials